After combining all the five CpG sites in IL21R amplicon, we revealed IL21R hypomethylation had a good discrimination ability for BC patients [benign vs. BC, area under curve (AUC) = 0.88, 95% CI: 0.85–0.91, Figure 4a]. The gene discussed is IL21R; the disease is breast cancer.